The evolving landscape of genetic biomarkers for immunotherapy in primary and metastatic breast cancer
This study revealed the distinctive mutational features of primary and R/M tumors in Chinese breast cancer patients, which are different from those from Western countries. The enrichment of <i>PD-L1</i> amplification in metastatic TNBC indicates the necessity to re-biopsy metastatic tumors for immunotherapy.
Authors
- Zijian Yang (ORCID: https://orcid.org/0009-0004-1265-3719)
- Pengli Yu (ORCID: https://orcid.org/0009-0004-7650-8422)
- Jun Zhang (ORCID: https://orcid.org/0000-0001-7886-6187)
- Yan Xu (ORCID: https://orcid.org/0000-0002-6693-8494)
- Rongrong Chen (ORCID: https://orcid.org/0000-0002-5362-2116)
- Wei Tang (ORCID: https://orcid.org/0009-0004-5346-8368)
- Liang Jin (ORCID: https://orcid.org/0000-0003-1854-1692)
Institutions
- Sun Yat-sen University (CN)
- Daping Hospital (CN)
- Sun Yat-sen Memorial Hospital (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou Development Zone Hospital (CN)
- Peking University Shenzhen Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.3389/fonc.2025.1522262
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05